VDM 11 (in Tocrisolve™ 100)

Discontinued Product

VDM 11 (in Tocrisolve™ 100) (Cat. No. 1686) has been withdrawn from sale for commercial reasons.
Description: Potent, selective anandamide transport inhibitor (in water-soluble emulsion)
Chemical Name: (5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide
Literature (2)

Biological Activity for VDM 11 (in Tocrisolve™ 100)

A potent and selective inhibitor of the anandamide membrane transporter (AMT), in water-soluble emulsion (for details see TocrisoveTM 100). IC50 values for inhibition of AMT are 4 - 11 mM. Displays negligible agonist activity at the hVR1 receptor and very weak action at CB1 and CB2 receptors. Ki values are > 5 - 10 mM at CB1 and CB2. Active in vivo.

VDM 11, pure oil dissolved in ethanol and Tocrisolve Control also available.

Technical Data for VDM 11 (in Tocrisolve™ 100)

M. Wt 409.61
Formula C27H39NO2
Storage Store at +4°C
CAS Number 313998-81-1
PubChem ID 9887748

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for VDM 11 (in Tocrisolve™ 100)

Certificate of Analysis / Product Datasheet
Select another batch:

References for VDM 11 (in Tocrisolve™ 100)

References are publications that support the biological activity of the product.

Bisogno et al (2001) The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur.J.Biochem. 268 1982 PMID: 11277920

De Petrocellis et al (2000) Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 483 52 PMID: 11033355

De Petrocellis et al (2001) The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J.Biol.Chem. 276 12856 PMID: 11278420

Gubellini et al (2002) Experimental Parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J.Neurosci. 22 6900 PMID: 12177188

View Related Products by Product Action

View all Cannabinoid Transporter Inhibitors

Keywords: VDM 11 (in Tocrisolve 100), VDM 11 (in Tocrisolve 100) supplier, Potent, selective, anandamide, transporters, inhibitors, inhibits, water-soluble, emulsion, AMT, Anandamide, cannabinoids, Monoamine, Neurotransmitter, VDM11, Tocrisolve100, Cannabinoid, Transporters, 1686, Tocris Bioscience

Citations for VDM 11 (in Tocrisolve™ 100)

Citations are publications that use Tocris products.

Currently there are no citations for VDM 11 (in Tocrisolve™ 100).

Reviews for VDM 11 (in Tocrisolve™ 100)

There are currently no reviews for this product. Be the first to review VDM 11 (in Tocrisolve™ 100) and earn rewards!

Have you used VDM 11 (in Tocrisolve™ 100)?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Cannabinoid Receptor Ligands Scientific Review

Cannabinoid Receptor Ligands Scientific Review

Written by Roger Pertwee, this review discusses compounds which affect the activity of the endocannabinoid system, focusing particularly on ligands that are most widely used as experimental tools and denotes compounds available from Tocris.

Addiction Poster

Addiction Poster

The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.